-
Product Insights
Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertrophic Cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, the sensation of rapid, fluttering, or pounding heartbeats, and heart murmur. HCM usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners. The HCM pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete...
-
Product Insights
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Stroke can occur with symptoms including sudden numbness in their face or limbs, particularly down one side of their body. The sufferer may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. The Stroke pipeline drugs market research report outlays comprehensive information on the Stroke targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...
-
Product Insights
Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality...
-
Product Insights
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in the lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men. The PVD pipeline drugs...
-
Product Insights
Behcet Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems. The Behcet Disease pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Product Insights
Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in the legs, ankles, and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse, and metabolic disorders, such as thyroid disease...
-
Product Insights
Left Ventricular Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heartbeat, and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism, and coronary artery disease. The left ventricular dysfunction drugs in development report provides an overview of the left ventricular dysfunction pipeline landscape. It provides comprehensive information on the therapeutics under development for left ventricular dysfunction, complete with analysis by stage of development, drug target, mechanism of...
-
Product Insights
Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to the leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs, and sores or wounds on the lower limb that heal slowly, and poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age, and family history. The intermittent claudication - drugs in development report provides an...
-
Product Insights
Acute Coronary Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Acute Coronary Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Acute Coronary Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news...
-
Product Insights
Acute Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Acute Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Acute Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.